Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Valbenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 known ✓ | Q05940 | 9/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valbenazine SCHEMBL871303 | 1.00 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL17565511 | 1.00 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL15932979 | 1.00 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL23119371 | 1.00 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL872246 | 1.00 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL23771726 | 1.00 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL20049776 | 1.00 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL19024486 | 1.00 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL17565518 | 1.00 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 | |
| Valbenazine SCHEMBL871304 | 1.00 | HTR1A (1.00) | HTR1ATBXA2RPTGS1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200347057-A1 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | AGNO PHARMA USA | 2020-11-05 | — | — | US | claimed |
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | disclosed |
| US-20240316035-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC | 2024-09-26 | — | — | US | disclosed |
| US-20240307371-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS LLC | 2024-09-19 | — | — | US | disclosed |
| US-20240239791-A1 | PROCESSES FOR THE SYNTHESIS OF VALBENAZINE | NEUROCRINE BIOSCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12016858-B2 | Methods for the treatment of abnormal involuntary movement disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-4344742-A2 | VALBENAZINE SALTS AND POLYMORPHS THEREOF | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-04-03 | — | — | EP | disclosed |
| US-11648244-B2 | Methods for the treatment of abnormal involuntary movement disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| JP-2023068137-A | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 2023-05-16 | — | — | JP | disclosed |
| US-20180208592-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS, INC. | 2018-07-26 | — | — | US | disclosed |
| US-20180169087-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180064701-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC | 2018-03-08 | — | — | US | disclosed |
| US-20170326131-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC | 2017-11-16 | — | — | US | disclosed |
| US-20170183346-A1 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | AGNO PHARMA USA | 2017-06-29 | — | — | US | disclosed |
| US-20170183346-A1 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | AGNO PHARMA USA | 2017-06-29 | — | — | US | disclosed |
| US-20170151227-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS INC (US) | 2017-06-01 | — | — | US | disclosed |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160287574-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160068526-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS, INC. | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | ACAT2, CPT1A, SLC18A2 | SLC18A2 3/4885HTR1A 747/4885TBXA2R 813/4885 |
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | DRD2, HTR2C, SLC18A2 | SLC18A2 3/4885HTR1A 18/4885TBXA2R 541/4885 |
| US-20170183346-A1 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11bR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11b-HEXAHYDRO-1H-PYRIDO[2,1-a]ISOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | CYP2S1, CYP26B1, CYP4B1 | SLC18A2 3875/4885HTR1A 158/4885TBXA2R 1082/4885 |
| US-11648244-B2 | Methods for the treatment of abnormal involuntary movement disorders | CKMT1A; CKMT1B, GYS1, MUSK | SLC18A2 13/4885HTR1A 316/4885TBXA2R 2052/4885 |
| US-20240307371-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | SLC18A2, SLC6A2, SLC18A1 | SLC18A2 1/4885HTR1A 146/4885TBXA2R 720/4885 |
| US-20240239791-A1 | PROCESSES FOR THE SYNTHESIS OF VALBENAZINE | SLC18A2, SLC18A3, SLC6A3 | SLC18A2 1/4885HTR1A 237/4885TBXA2R 2254/4885 |
| US-20170326131-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | CKMT1A; CKMT1B, GYS1, MUSK | SLC18A2 13/4885HTR1A 316/4885TBXA2R 2052/4885 |
| US-20160287574-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | CKMT1A; CKMT1B, GYS1, MUSK | SLC18A2 13/4885HTR1A 316/4885TBXA2R 2052/4885 |
| US-20180169087-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | SLC18A2, SLC6A2, SLC18A1 | SLC18A2 1/4885HTR1A 146/4885TBXA2R 720/4885 |
| US-20160068526-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | ACAT2, CPT1A, SLC18A2 | SLC18A2 3/4885HTR1A 747/4885TBXA2R 813/4885 |
| US-20160303110-A1 | METHODS OF TREATING ABNORMAL MUSCULAR ACTIVITY | PYGM, TNNC1, MUSK | SLC18A2 524/4885HTR1A 1559/4885TBXA2R 1406/4885 |
| US-20170151227-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | CKMT1A; CKMT1B, GYS1, MUSK | SLC18A2 13/4885HTR1A 316/4885TBXA2R 2052/4885 |
| US-20200347057-A1 | SYNTHETIC METHODS FOR PREPARATION OF (S)-(2R,3R,11BR)-3-ISOBUTYL-9,10-DIMETHOXY-2,3,4,6,7,11B-HEXAHYDRO-1H-PYRIDO[2,1,-A]lSOQUINOLIN-2-YL 2-AMINO-3-METHYLBUTANOATE DI(4-METHYLBENZENESULFONATE) | CYP2S1, CYP26B1, UGT2B7 | SLC18A2 3816/4885HTR1A 202/4885TBXA2R 781/4885 |
| US-20240316035-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | CKMT1A; CKMT1B, GYS1, MUSK | SLC18A2 13/4885HTR1A 316/4885TBXA2R 2052/4885 |
| US-12016858-B2 | Methods for the treatment of abnormal involuntary movement disorders | CKMT1A; CKMT1B, GYS1, MUSK | SLC18A2 13/4885HTR1A 316/4885TBXA2R 2052/4885 |
| US-20180064701-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | CKMT1A; CKMT1B, GYS1, MUSK | SLC18A2 13/4885HTR1A 316/4885TBXA2R 2052/4885 |
| US-20180208592-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | ACAT2, CPT1A, SLC18A2 | SLC18A2 3/4885HTR1A 747/4885TBXA2R 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.